Immunocore

Immunocore, Genentech collaborate on cancer targets

Tuesday, July 2, 2013

Immunocore, an Oxford-based biotechnology company developing novel biological drugs known as ImmTACs to treat cancer and viral disease, has entered a research collaboration and licensing agreement with Genentech, a member of the Roche Group, for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology.

[Read More]